ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it
intends to offer and sell, subject to market and other conditions,
shares of its common stock in an underwritten public offering. There can
be no assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Jefferies LLC and Cowen and Company, LLC are acting as the joint
book-running managers for the offering. JMP Securities LLC and Needham &
Company, LLC are acting as co-managers for the offering.
The shares of common stock described above are being offered by ACADIA
pursuant to a shelf registration statement previously filed by ACADIA
with the Securities and Exchange Commission (SEC) and declared effective
by the SEC on January 6, 2012. A preliminary prospectus supplement
related to the offering will be filed with the SEC and will be available
on the SEC's website located at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to this offering, when available, may be obtained
from Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 12th floor, New York, NY 10022 or by telephone at
877-547-6340 or by email at Prospectus_Department@Jefferies.com,
or from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department,
Phone: 631-274-2806, Fax: 631-254-7140).
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on innovative treatments
that address unmet medical needs in neurological and related central
nervous system disorders. ACADIA has a pipeline of product candidates
led by pimavanserin, which is in Phase III development as a treatment
for Parkinson's disease psychosis. ACADIA also has clinical-stage
programs for chronic pain and glaucoma in collaboration with Allergan,
Inc. and two advanced preclinical programs directed at Parkinson’s
disease and other neurological disorders. All product candidates are
small molecules that emanate from discoveries made at ACADIA.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the proposed offering of common
stock by ACADIA. These statements are only predictions based on current
information and expectations and involve a number of risks and
uncertainties. Actual events or results may differ materially from those
projected in any of such statements due to various factors, including
market risks and uncertainties and the satisfaction of customary closing
conditions for an offering of securities. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2012 as well as ACADIA’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
<div class="copyright">
Copyright Business Wire 2013
</div>